BioSpace News Archive

PrecisionLife Reports 14 Genes Associated with ME/CFS at the M.E. Genetics Research Summit in Edinburgh

The acute repetitive seizure is a condition that occurs in patients with drug-refractory epilepsy. It is also known as cluster seizure, seizure flurry, breakthrough seizure, seizure cluster, serial seizure, or prolonged seizure.

New Zealand based soft tissue regeneration company Aroa Biosurgery (AROA) is delighted to announce the appointment of award-winning medical researcher and inventor, Dr. Catherine Mohr as a Non-Executive Director to the board.

Sensorion announces that the first patient has been enrolled in its proof-of-concept clinical trial of SENS-401 in patients scheduled for cochlear implantation.

Transcenta Holding Limited announces that TST003, its first-in-class, high affinity humanized monoclonal antibody targeting Gremlin1, has received IND clearance from U.S. Food and Drug Administration.

Pharnext SA announces the publication of symptom burden findings of Charcot-Marie-Tooth Disease Type1A from the ‘Real-World’ Digital Lifestyle Study, CMT&Me, in the Journal of Clinical Neuromuscular Disease.

Samsung Bioepis Co., Ltd. announced that it has attained two ISO certifications: ISO 140001 and ISO 50001 from Lloyd’s Register Quality Assurance, reflecting the company’s ongoing practices and commitment to becoming a sustainable company.

Revive Therapeutics Ltd. announced that it has filed an amended protocol to the U.S. Food & Drug Administration for the Company’s Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19.

About 66% of U.S. residences burn methane gas, wood, propane, heating oil or other fuel for heating, drying clothes and cooking food.

Pfizer Inc. announced that the first participants have been dosed in a pivotal Phase 3 clinical trial to evaluate the efficacy, safety, tolerability and immunogenicity of the company’s quadrivalent modified RNA influenza vaccine candidate in approximately 25,000 healthy U.S. adults.